Literature DB >> 25251245

Low ficolin-2 levels in common variable immunodeficiency patients with bronchiectasis.

M-L Metzger1, I Michelfelder, S Goldacker, K Melkaoui, J Litzman, D Guzman, B Grimbacher, U Salzer.   

Abstract

Common variable immunodeficiency (CVID) encompasses a heterogeneous group of antibody deficiencies characterized by susceptibility to recurrent infections and sequelae, including bronchiectasis. We investigated the relevance of the lectin complement pathway in CVID patients by analysing ficolin-2 and ficolin-3 serum levels and genotyping single nucleotide polymorphisms (SNPs) in the FCN2 and FCN3 genes. Our results show that ficolin-2 levels in CVID patients are significantly lower (P < 0.0001) than in controls. The lowest ficolin-2 levels are found in CVID patients with bronchiectasis (P = 0.0004) and autoimmunity (P = 0.04). Although serum levels of ficolin-3 were similar in CVID patients and controls, CVID patients with bronchiectasis again showed lower levels when compared to controls (P = 0.0001). Analysis of single nucleotide polymorphisms in the FCN2 gene confirmed known influences on ficolin-2 serum levels, but did not support a genetic basis for the observed ficolin-2 deficiency in CVID. We found that CVID patients with bronchiectasis have very low levels of ficolin-2. The reason for the deficiency of ficolin-2 in CVID and any possible causal relationship is currently unknown. However, as bronchiectasis is a very important factor for morbidity and mortality in CVID, ficolin-2 could also serve as biomarker for monitoring disease complications such as bronchiectasis.
© 2014 British Society for Immunology.

Entities:  

Keywords:  CVID; complement; ficolin-2; ficolin-3; lectin pathway

Mesh:

Substances:

Year:  2015        PMID: 25251245      PMCID: PMC4298403          DOI: 10.1111/cei.12459

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  35 in total

1.  Ficolin-2 recognizes DNA and participates in the clearance of dying host cells.

Authors:  Maria Lund Jensen; Christian Honoré; Tina Hummelshøj; Bjarke Endel Hansen; Hans Ole Madsen; Peter Garred
Journal:  Mol Immunol       Date:  2006-05-26       Impact factor: 4.407

2.  A novel human serum lectin with collagen- and fibrinogen-like domains that functions as an opsonin.

Authors:  M Matsushita; Y Endo; S Taira; Y Sato; T Fujita; N Ichikawa; M Nakata; T Mizuochi
Journal:  J Biol Chem       Date:  1996-02-02       Impact factor: 5.157

3.  Effect of capsulation of opportunistic pathogenic bacteria on binding of the pattern recognition molecules mannan-binding lectin, L-ficolin, and H-ficolin.

Authors:  Anders Krarup; Uffe B Skov Sørensen; Misao Matsushita; Jens C Jensenius; Steffen Thiel
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

4.  The impact of FCN2 polymorphisms and haplotypes on the Ficolin-2 serum levels.

Authors:  L Munthe-Fog; T Hummelshøj; B E Hansen; C Koch; H O Madsen; K Skjødt; P Garred
Journal:  Scand J Immunol       Date:  2007-04       Impact factor: 3.487

5.  Polymorphisms in the FCN2 gene determine serum variation and function of Ficolin-2.

Authors:  Tina Hummelshoj; Lea Munthe-Fog; Hans O Madsen; Teizo Fujita; Misao Matsushita; Peter Garred
Journal:  Hum Mol Genet       Date:  2005-05-06       Impact factor: 6.150

Review 6.  The role of mannose-binding lectin in health and disease.

Authors:  M W Turner
Journal:  Mol Immunol       Date:  2003-11       Impact factor: 4.407

Review 7.  Common variable immune deficiency: respiratory manifestations, pulmonary function and high-resolution CT scan findings.

Authors:  K M Thickett; D S Kumararatne; A K Banerjee; R Dudley; D E Stableforth
Journal:  QJM       Date:  2002-10

8.  Deficiency of somatic hypermutation of the antibody light chain is associated with increased frequency of severe respiratory tract infection in common variable immunodeficiency.

Authors:  Pernille Andersen; Henrik Permin; Vagn Andersen; Lone Schejbel; Peter Garred; Arne Svejgaard; Torben Barington
Journal:  Blood       Date:  2004-09-14       Impact factor: 22.113

9.  No strong relationship between mannan binding lectin or plasma ficolins and chemotherapy-related infections.

Authors:  D C Kilpatrick; L A McLintock; E K Allan; M Copland; T Fujita; N E Jordanides; C Koch; M Matsushita; H Shiraki; K Stewart; M Tsujimura; M L Turner; I M Franklin; T L Holyoake
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

Review 10.  Human Mannose-binding Lectin in Immunity: Friend, Foe, or Both?

Authors:  Jean-Laurent Casanova; Laurent Abel
Journal:  J Exp Med       Date:  2004-05-17       Impact factor: 14.307

View more
  11 in total

1.  Alcohol Consumption Modulates Host Defense in Rhesus Macaques by Altering Gene Expression in Circulating Leukocytes.

Authors:  Tasha Barr; Thomas Girke; Suhas Sureshchandra; Christina Nguyen; Kathleen Grant; Ilhem Messaoudi
Journal:  J Immunol       Date:  2015-11-30       Impact factor: 5.422

2.  Lectin pathway factors in patients suffering from juvenile idiopathic arthritis.

Authors:  Katarzyna Kasperkiewicz; Łukasz Eppa; Anna S Świerzko; Marcin A Bartłomiejczyk; Zbigniew M Żuber; Katarzyna Siniewicz-Luzeńczyk; Elżbieta Mężyk; Misao Matsushita; Leokadia Bąk-Romaniszyn; Krzysztof Zeman; Mikael Skurnik; Maciej Cedzyński
Journal:  Immunol Cell Biol       Date:  2017-04-13       Impact factor: 5.126

3.  Ficolin-3 Deficiency Is Associated with Disease and an Increased Risk of Systemic Lupus Erythematosus.

Authors:  Anne Troldborg; Rudi Steffensen; Marten Trendelenburg; Thomas Hauser; Kasper G Winther; Annette G Hansen; Kristian Stengaard-Pedersen; Anne Voss; Steffen Thiel
Journal:  J Clin Immunol       Date:  2019-05-01       Impact factor: 8.317

4.  The Plasma Proteome Fingerprint Associated with Circulating Carotenoids and Retinol in Older Adults.

Authors:  Yuko Yamaguchi; Marta Zampino; Toshiko Tanaka; Stefania Bandinelli; Ruin Moaddel; Giovanna Fantoni; Julián Candia; Luigi Ferrucci; Richard D Semba
Journal:  J Nutr       Date:  2022-01-11       Impact factor: 4.687

5.  Association of the FCN2 Gene Single Nucleotide Polymorphisms with Susceptibility to Pulmonary Tuberculosis.

Authors:  Dan-Dan Xu; Chong Wang; Feng Jiang; Li-Liang Wei; Li-Ying Shi; Xiao-Mei Yu; Chang-Ming Liu; Xue-Hong Liu; Xian-Min Feng; Ze-Peng Ping; Ting-Ting Jiang; Zhong-Liang Chen; Zhong-Jie Li; Ji-Cheng Li
Journal:  PLoS One       Date:  2015-09-17       Impact factor: 3.240

6.  Role of lectin pathway complement proteins and genetic variants in organ damage and disease severity of systemic sclerosis: a cross-sectional study.

Authors:  Michael Osthoff; Veronika K Jaeger; Ingmar A F M Heijnen; Marten Trendelenburg; Suzana Jordan; Oliver Distler; Ulrich A Walker
Journal:  Arthritis Res Ther       Date:  2019-03-18       Impact factor: 5.156

7.  Insufficient serum L-ficolin is associated with disease presence and extent of pulmonary Mycobacterium avium complex disease.

Authors:  Tomofumi Kobayashi; Koji Kuronuma; Atsushi Saito; Kimiyuki Ikeda; Shigeru Ariki; Atsushi Saitou; Mitsuo Otsuka; Hirofumi Chiba; Satoshi Takahashi; Motoko Takahashi; Hiroki Takahashi
Journal:  Respir Res       Date:  2019-10-21

8.  Frequency and distribution of FCN2 and FCN3 functional variants among MBL2 genotypes.

Authors:  Helga Bjarnadottir; Margret Arnardottir; Bjorn Runar Ludviksson
Journal:  Immunogenetics       Date:  2016-01-21       Impact factor: 2.846

9.  Six-SOMAmer Index Relating to Immune, Protease and Angiogenic Functions Predicts Progression in IPF.

Authors:  Shanna L Ashley; Meng Xia; Susan Murray; David N O'Dwyer; Ethan Grant; Eric S White; Kevin R Flaherty; Fernando J Martinez; Bethany B Moore
Journal:  PLoS One       Date:  2016-08-04       Impact factor: 3.240

10.  Human Amnion-Derived Mesenchymal Stromal Cells: A New Potential Treatment for Carbapenem-Resistant Enterobacterales in Decompensated Cirrhosis.

Authors:  Mariangela Pampalone; Giampiero Vitale; Salvatore Gruttadauria; Giandomenico Amico; Gioacchin Iannolo; Bruno Douradinha; Alessandra Mularoni; Pier Giulio Conaldi; Giada Pietrosi
Journal:  Int J Mol Sci       Date:  2022-01-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.